KALA BIO Management

Management criteria checks 2/4

KALA BIO's CEO is Mark Iwicki, appointed in Sep 2015, has a tenure of 9.17 years. total yearly compensation is $8.34M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 1.57% of the company’s shares, worth $474.55K. The average tenure of the management team and the board of directors is 6.5 years and 7.2 years respectively.

Key information

Mark Iwicki

Chief executive officer

US$8.3m

Total compensation

CEO salary percentage	8.5%
CEO tenure	9.2yrs
CEO ownership	1.6%
Management average tenure	6.5yrs
Board average tenure	7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Iwicki's remuneration changed compared to KALA BIO's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$39m
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$8m	US$709k	-US$42m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$682k	-US$45m
Sep 30 2022	n/a	n/a	-US$80m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$145m
Dec 31 2021	US$3m	US$644k	-US$143m
Sep 30 2021	n/a	n/a	-US$126m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$5m	US$586k	-US$104m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$90m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$3m	US$564k	-US$94m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$90m
Mar 31 2019	n/a	n/a	-US$81m
Dec 31 2018	US$3m	US$535k	-US$67m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$501k	-US$42m

Compensation vs Market: Mark's total compensation ($USD8.34M) is above average for companies of similar size in the UK market ($USD356.31K).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Iwicki (58 yo)

9.2yrs

Tenure

US$8,342,714

Compensation

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Iwicki	Chairman & CEO	9.2yrs	US$8.34m	1.57% $ 474.6k
Todd Bazemore	President & COO	7yrs	US$2.94m	0.49% $ 146.6k
R. Brazzell	Head of R&D and Chief Medical Officer	11.8yrs	US$2.92m	0.54% $ 161.7k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	no data	no data
Mary Reumuth	CFO & Treasurer	10.8yrs	no data	0.35% $ 105.2k
Jill Steier	Executive Director of Investor Relations & Corporate Communications	3.3yrs	no data	no data
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	7.3yrs	no data	no data
Darius Kharabi	Chief Business Officer	3yrs	no data	0.48% $ 145.1k
Francis Mah	Chief Medical Advisor	1.7yrs	no data	no data
Josiah Craver	Senior VP & Corporate Controller	2.6yrs	no data	no data
Carl Rennie	Executive Director of Account Management	6.5yrs	no data	no data
Patrick Bedell	Executive Director of Trade & Alternate Channels	6.5yrs	no data	no data

6.5yrs

Average Tenure

56yo

Average Age

Experienced Management: 0JQ2's management team is seasoned and experienced (6.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Iwicki	Chairman & CEO	9.6yrs	US$8.34m	1.57% $ 474.6k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	no data	no data
Jonathan Silverstein	Board Observer	8.6yrs	no data	no data
Gregory Perry	Independent Director	6.8yrs	US$302.01k	0.051% $ 15.5k
Peter Hutt	Member of Scientific Advisory Board	no data	no data	no data
Andrew Koven	Lead Independent Director	7.2yrs	US$402.36k	0.066% $ 20.0k
Ronald Krall	Member of Scientific Advisory Board	no data	no data	no data
Bennett Shapiro	Member of Scientific Advisory Board	no data	no data	no data
Colin Gardner	Member of Scientific Advisory Board	no data	no data	no data
Charles Myers	Independent Director	3.1yrs	US$236.94k	0.029% $ 8.7k
Howard Rosen	Independent Director & Member of Advisory Board	10.8yrs	US$392.20k	0.065% $ 19.7k
Marjan Farid	Independent Director	2.1yrs	US$225.64k	0.024% $ 7.2k

7.2yrs

Average Tenure

66yo

Average Age

Experienced Board: 0JQ2's board of directors are considered experienced (7.2 years average tenure).

KALA BIO Management

Management criteria checks 2/4

Key information

Recent management updates

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Insufficient new directors

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Recent updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age